Dupixent (Dupilumab) Denied by Insurance: Appeal Guide

Dupixent (dupilumab) is a biologic injectable medication developed by Sanofi and Regeneron that targets the IL-4 and IL-13 pathways, two key drivers of type 2 inflammatory disease. It is FDA-approved for moderate-to-severe atopic dermatitis (eczema), moderate-to-severe asthma with an eosinophilic phenotype, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, prurigo nodularis, and alopecia areata. Despite strong clinical evidence and no black box warnings, Dupixent is denied by insurance at a frustratingly high rate — often due to rigid step therapy protocols and Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization requirements.

Why Insurance Denies Dupixent

Step therapy requiring topical steroids first is the most common barrier for atopic dermatitis patients. Most insurers require documented failure of multiple topical treatments before approving a biologic. This typically includes medium- and high-potency topical corticosteroids, topical calcineurin inhibitors (such as tacrolimus or pimecrolimus), and sometimes phototherapy. For moderate-to-severe eczema, these treatments frequently fail or cause significant side effects — but insurers want to see documented evidence of that failure before unlocking Dupixent.

Prior authorization is mandatory across all indications. Your insurer's PA criteria typically require a confirmed diagnosis, documentation of disease severity, evidence of prior treatment failure, and sometimes specific lab values or test results (such as blood eosinophil counts for the asthma indication).

Severity threshold denials are common for asthma. Dupixent for asthma is indicated for moderate-to-severe disease with an eosinophilic or oral corticosteroid-dependent phenotype. If an insurer determines your asthma does not meet their internal definition of severe, or if your eosinophil counts do not meet their threshold, they may deny even a correct prescription.

Off-label denials can occur when a physician prescribes Dupixent for an indication that is FDA-approved but not yet reflected in the insurer's coverage policy. Policy updates sometimes lag behind FDA decisions by months or even years.

Building Your Dupixent Appeal

Compile objective severity scores. For atopic dermatitis, document your EASI (Eczema Area and Severity Index) score, SCORAD (SCORing Atopic Dermatitis) score, or IGA (Investigator Global Assessment) score. A score of moderate or higher (EASI 16+, SCORAD 25+, or IGA 3 or 4) supports medical necessity for a biologic. For asthma, provide eosinophil counts, FEV1 values, and a log of exacerbations requiring oral corticosteroids.

Detail every prior treatment and why it failed. Your appeal must list each topical or systemic therapy you tried — the drug name, dosage, duration, and reason for discontinuation or inadequate response. Side effects such as skin thinning from prolonged steroid use, cataracts, or adrenal suppression are valid reasons for switching to a non-steroidal biologic.

Request a letter of medical necessity. Your dermatologist, allergist, or pulmonologist should draft a letter explaining the specific reason Dupixent is appropriate for your case, citing your severity scores and treatment history. This letter should also address why continuing step therapy would cause harm.

Cite the clinical evidence. The pivotal SOLO, SOLO 2, and LIBERTY AD CHRONOS trials for atopic dermatitis demonstrated clear superiority over placebo for moderate-to-severe disease. Reference these studies — and relevant AAD or AAAAI treatment guidelines — in your appeal to show that your doctor's recommendation is evidence-based.

Use peer-to-peer review. Have your prescribing physician call the insurer's medical director directly. Specialist-to-reviewer conversations resolve denials faster than written appeals in many cases, particularly when the physician can explain the nuances of your disease course.

Escalate to External Independent Review: Complete Guide" class="auto-link">external review. If your internal appeal is denied, you have the right to an independent external review. Dupixent denials are often overturned at this stage because the drug has strong clinical backing and few comparable alternatives for patients who have failed step therapy.

State Step Therapy Protections

Many states have enacted step therapy override laws requiring insurers to grant exceptions quickly when a physician certifies that the required first-line drugs are medically inappropriate. Check whether your state has such a law, and if so, have your physician file a formal step therapy exception request in addition to your appeal. This process is often faster and more effective than a standard appeal.

Patient Assistance Programs

Sanofi and Regeneron offer Dupixent MyWay, a patient support program that includes copay assistance for commercially insured patients (reducing out-of-pocket costs to as little as zero for eligible patients), as well as free drug for qualifying uninsured or underinsured patients. Visit dupixentmyway.com or call 1-844-DUPIXENT for details.

Dupixent costs approximately $37,000–$40,000 per year at list price, so pursuing all available assistance is critical while your appeal is pending. Do not delay contacting Dupixent MyWay — enrollment can take time, and temporary supply options may be available while your appeal is processed.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?